BioLoomics

BioLoomics is a preclinical-stage biotechnology company headquartered in Boulder, Colorado, developing next-generation antibody-drug conjugates (ADCs) and targeted protein degradation therapeutics. The company leverages directed evolution and AI-assisted antibody engineering to create what it calls 'Super-ADCs' — highly potent, precision-targeted therapeutics designed to selectively eliminate disease-causing proteins in cancer and other serious conditions. BioLoomics raised an $8.7 million seed round led by Innovation Endeavors to emerge from stealth. Its platform combines proprietary antibody discovery methods with cutting-edge payload and linker chemistry to generate candidates with improved therapeutic windows compared to conventional ADCs. The company's pipeline spans oncology targets, with scientific programs in antibody-drug conjugates, directed evolution of binding proteins, and targeted protein degradation. BioLoomics is led by founder and CEO Iddo Weiner.